Crohn'sRecruiting

Intestinal Ischemia Biomarker in Patients With Chronic Mesenteric Ischemia

Observational · No treatment assigned · 1 site · Oslo University Hospital

Official record & contacts on ClinicalTrials.gov ↗

In plain English

What this trial is testing

Condition(s) listed: Chronic Mesenteric Ischemia, Median Arcuate Ligament Syndrome and Crohn Disease. This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.

Who can join

Ages 18 and older
Any sex
Healthy volunteers accepted

Some of the main requirements, copied from the record:

For the patient groups :
Group 1: Has CTA or ultrasound diagnosed MALS and is scheduled operative treatment.
Group 2: Has CTA or ultrasound diagnosed CMI and is scheduled operative or endovascular treatment.

Plus 4 more requirement(s). Only the trial team can confirm whether you qualify.

What's involved

About 180 participants are expected to take part.
Start date: 2024-06-10.
Main results expected around 2037-05-31 (estimate from the record).
1 study site listed (1 marked recruiting) in Norway.

Main thing being measured

Plasma alpha Glutathione S transferase (3 months)

In the researchers’ words

Plasma Alpha glutathione S transferase (Alpha GST) has been previously demonstrated to be raised in patients with chronic mesenteric ischemia (CMI) caused by atherosclerosis and in patients with median arcuate ligament syndrome (MALS). Raised plasma level of Alpha GST has been demonstrated to decrease or normalize after surgical treatment of patients with CMI and MALS as compared with healthy individuals.

This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.

Questions to ask your doctor and the trial team

Am I likely to qualify, given my health history?
What would I have to do, and how often would I need to visit?
Could I get a placebo? What happens to my current treatment?
What are the possible risks and benefits?
Are travel or other costs covered?
What happens after the trial ends?

Official details

Status	Recruiting
Phase	Observational
Study type	Observational
Conditions	Chronic Mesenteric Ischemia; Median Arcuate Ligament Syndrome; Crohn Disease; Cholelithiasis
Lead sponsor	Oslo University Hospital
Enrollment	180 (estimated)
Start date	2024-06-10
Primary completion (est.)	2037-05-31
First posted	2024-06-21
Last updated	2025-07-30
Official title	Intestinal Ischemia Biomarker and Quality of Life of the Patients With Chronic Mesenteric Ischemia and Median Arcuate Ligament Syndrome
ClinicalTrials.gov ID	NCT06468774

Interventions

Laparoscopic surgery (Procedure)
The patients in the MALS group will be treated through transperitoneal ventral approach for the laparoscopic release of the celiac artery. Median arcuate ligament and any muscle or nerve tissue crossing the cranial surface of the celiac artery will be divided to release the celiac artery from compression. In the patients with CMI open antegrade or retrograde bypass to celiac artery or superior me…

Full eligibility criteria (from the record)

Inclusion Criteria: Above 18 years and has given informed written consent for treatment and study participation

For the patient groups :

Group 1: Has CTA or ultrasound diagnosed MALS and is scheduled operative treatment.

Group 2: Has CTA or ultrasound diagnosed CMI and is scheduled operative or endovascular treatment.

For the control group:

Group 3- Has ultrasound based diagnosis of cholelithiasis and is scheduled for cholecystectomy.

Group 4- Has established Mb Crohn diagnosis and under gastric lab follow-up. Group 5- Young healthy blood donors of mean age 45 years and has excluded MALS or CMi with ultrasound.

Group 6- Healthy blood donors of mean age 70 years and has excluded MALS or CMi with ultrasound.

Exclusion Criteria: Age less than 18 years Has nor given written consent.

\-

Locations (1)

Site	City	Country	Site status
Department of vascular surgery, Oslo University Hospital	Oslo, Oslo	Norway	Recruiting

For contacts at each site, use the official record.

Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.